Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study

ConclusionsGlobalagliatin was well tolerated and showed favorable pharmacokinetic profiles in Chinese patients with type 2 diabetes. High-dose globalagliatin reduced plasma glucose, and improved insulin resistance.Trial RegistrationClinicaltrials.gov indentifier, NCT03414892.

Source: Clinical Drug Investigation - October 30, 2020 Category: Drugs & Pharmacology Source Type: research